Cardiac Insight

Cardiac Insight is a medical device company specializing in point-of-care cardiac diagnostics for sports medicine and clinical cardiology. The company develops two primary products: the Cardea 20/20, a handheld 12-lead ECG device with athlete-specific algorithms that achieves an approximately two percent false-positive rate for detecting cardiovascular conditions in athletes using International Consensus Criteria, and the Cardea SOLO, a lightweight wearable ambulatory ECG sensor that continuously records for up to seven days with software-assisted analysis generating reports in under five minutes. The Cardea SOLO system includes a wireless sensor, USB smart cable for data transfer, and clinical software providing draft summary reports, trace views, beat morphology analysis, and calipers. Pioneered by Dr. Dave Hadley and Dr. Vic Froelicher, the company joined forces with DreamTech in 2021 to expand its cardiac healthcare diagnostics capabilities. Founded in 2008 and headquartered in Bellevue, Washington, Cardiac Insight has raised approximately $37.2 million through Series D funding from investors including SeaChange Fund, Welch Allyn, Washington Research Foundation, and Northwest Venture Associates.